Population pharmacokinetic modelling of roflumilast and roflumilastn-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model

Clinical Pharmacokinetics

Volumn 49, Issue 9, 2010, Pages 589-606

  Lahu, Gezim ^a,b   Hnnemeyer, Andreas ^a   Diletti, Edgar ^a   Elmlinger, Martin ^a   Ruth, Peter ^b   Zech, Karl ^a   McCracken, Nigel ^a   Facius, Axel ^a  

^a Nycomed GmbH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Adverse drug reactions; Pharmacodynamic modelling; Pharmacokinetic modelling; Pharmacokinetic pharmacodynamic relationships; pharmacokinetics; pharmacokinetics.; Population pharmacokinetics; Research and development; Roflumilast; Type 4 cyclic nucleotide phosphodiesterase inhibitors

Indexed keywords

NITRIC OXIDE; PHOSPHODIESTERASE IV; ROFLUMILAST; ROFLUMILAST N OXIDE; UNCLASSIFIED DRUG;

AGE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARTMENT MODEL; DRUG ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MODEL; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING;

ADULT; AGED; AMINOPYRIDINES; AREA UNDER CURVE; BENZAMIDES; CYCLOPROPANES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77955443662     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11536600-000000000-00000     Document Type: Article

References (51)

1. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory po-tential of the novel PDE4 inhibitor roflumilast in vitro. JPharmacol Exp Ther 2001; 297 (1): 267-279
2. Jones NA, Boswell-Smith V, Lever R, et al. The effect of selective phospho-diesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005; 18 (2): 93-101
3. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001; 297 (1): 280-290
4. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62 (12): 1081-1087
5. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast insevere chronic obstructive pulmonary disease. Am JRespir Crit Care Med 2007; 176 (2): 154-161
6. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366 (948): 563-571
7. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374 (9691): 685-694
8. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374 (9691): 695-703
9. Bethke TD, Bohmer GM, Hermann R, et al. Dose-proportional intra-individual single-and repeated-dose pharmacokinetics ofroflumilast, an oral, once-daily phosphodiesterase4inhibitor. JClin Pharmacol 2007; 47 (1): 26-36
10. Hauns B, Hermann R, Hunnemeyer A, et al. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46 (10): 1146-1153 (Pubitemid 44387414)
11. Lahu G, Hunnemeyer A, Herzog R, et al. Effect of repeated dose of erythro-mycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 2009; 47 (4): 236-245
12. Lahu G, Hunnemeyer A, von Richter O, et al. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol 2008; 48 (11): 1339-1349
13. von Richter O, Lahu G, Hunnemeyer A, et al. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmaco-kinet 2007; 46 (7): 613-622
14. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44 (1): 33-60
15. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004; 76 (6): 618-627
16. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6-14
17. Funck-Brentano C, RaphaelM,Lafontaine M, et al. Effects of typeofsmoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. Lung Cancer 2006; 54 (1): 11-18
18. Hermann R, Siegmund W, Giessmann T, et al. The oral, once-daily phos-phodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol 2007; 47 (8): 1005-1013
19. Hermann R, Nassr N, Lahu G, et al. Steady-state pharmacokinetics of ro-flumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007; 46 (5): 403-416
20. David M, Zech K, Seiberling M, et al. Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high oral bioavailability. J Allergy Clin Immunol 2004; 113: S220-1
21. Nassr N, Lahu G, Hunnemeyer A, et al. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. J Clin Pharmacol 2007; 47 (5): 660-666
22. Hermann R, Lahu G, Hauns B, et al. 'Total PDE4 inhibitory activity': a con-cept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions [abstract no. 2542]. Eur Respir J 2006; 28 Suppl. 50: 436s [online]. Available from URL: http://www.ers-education.org/pages/default.aspx?id=335&idBrowse= 7697&det=1 [Accessed 2010 Jun 14]
23. Manning CD, Burman M, Christensen SB, et al. Suppression of human in-flammatory cell function bysubtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999; 128 (7): 1393-1398
24. Halpin DM. ABCD of the phosphodiesterase family: interaction and differ-ential activity in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 543-561
25. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstruc-tive pulmonary disease. Lancet 2005; 365 (9454): 167-175
26. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003; 63 (23): 2575-94
27. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155 (3): 308-15
28. Kowalski KG, Hutmacher MM. Efficient screeningof covariatesin population models using Wald's approximation to the likelihood ratio test. J Pharmaco-kinet Pharmacodyn 2001; 28 (3): 253-275
29. Altana Pharma. Effect of roflumilast on pulmonary function and respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD) (BY217/M2-110) [ClinicalTrials.gov identifier NCT00062582].
30. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00062582?id= NCT00062582&rank=1 [Accessed 2010 Jun 14] Data on file, Nycomed GmbH, 2009
31. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton (FL): Chapman and Hall/CRC, 1993
32. Wang DD, Zhang S. Standardized visual predictive check: how and when to use it model validation [abstract no. 1501]. 18th Annual Meeting, Population Approach Group in Europe; 2009 Jun 23-26; St Petersburg [online]. Available from URL: http://www.page-meeting.org/default.asp?abstract=1501 [Accessed 2010 Jun 14]
33. Maintenance and Support Services Organization. The medical dictionary for regulatory activities. Chantilly (VA): Northrop Grumman Corporation, 2010
34. Egan J. Signal detection theory and ROC analysis. New York: Academic Press, 2010
35. Chambers JM, Cleveland WS, Kleiner B, et al. Graphical methods for data analysis. Boston (MA): Wadsworth & Brooks/Cole, 1983: 62
36. Bonate P. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer, 2006
37. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50 (2): 222-239
38. McCune JS, Lindley C, Decker JL, et al. Lack of gender differences and large intrasubject variabilityin cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 2001; 41 (7): 723-731
39. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44 (2): 275-283
40. Parkinson A, Mudra DR, Johnson C,et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver micro-somes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199 (3): 193-209
41. Strum DP, Eger EI, Unadkat JD, et al. Age affects the pharmacokinetics of inhaled anesthetics in humans. Anesth Analg 1991; 73 (3): 310-318
42. Wynne HA, Mutch E, James OF, et al. The effect of age upon the affinity of microsomal mono-oxygenase enzymes for substrate in human liver. Age Ageing 1988; 17 (6): 401-405
43. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5-promoter region polymorphism. Clin Pharmacol Ther 2000; 68 (1): 82-91
44. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syn-drome? Lancet 2007; 370 (9589): 797-799
45. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflam-matory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55 (2): 114-120
46. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor in-duces cachexia, anemia, and inflammation. J Exp Med 1988; 167 (3): 1211-1227
47. Masubuchi Y, Enoki K, Horie T. Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis. Drug Metab Dispos 2008; 36 (3): 597-603
48. Nassr N, Lahu G, von Richter O, et al. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects. Br J Clin Pharmacol 2007; 63 (3): 365-70 Data on file, Nycomed GmbH, 2007
49. Bohmer GM, Nassr N, Wenger M, et al. The targeted oral, once-daily phos-phodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. J Clin Pharmacol 2009; 49 (4): 389-397
50. Bethke TD, Giessmann T, Westphal K, et al. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Int J Clin Pharmacol Ther 2006; 44 (11): 572-579
51. Nassr N, Hunnemeyer A, Herzog R, et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009; 68 (4): 580-7 Data on file, Nycomed GmbH, 2005 Data on file, Nycomed GmbH, 2002 Data on file, Nycomed GmbH, 2001 Data on file, Nycomed GmbH, 2000